2. Search Result
Search Result
Results for "

secondary hyperparathyroidism

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Peptides

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109106A
    Upacicalcet sodium

    		CaSR Endocrinology
    Upacicalcet sodium is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels, by acting directly on parathyroid cell membrane calcium-sensing receptors. Upacicalcet can be used for researching the disease of secondary hyperparathyroidism (SHPT) .
    Upacicalcet sodium
  • HY-109106B
    (Rac)-Upacicalcet

    		CaSR Endocrinology
    (Rac)-Upacicalcet is the racemate of Upacicalcet.Upacicalcet is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels, by acting directly on parathyroid cell membrane calcium-sensing receptors. Upacicalcet can be used for researching the disease of secondary hyperparathyroidism (SHPT) .
    (Rac)-Upacicalcet
  • HY-P1955A
    Etelcalcetide hydrochloride
    1 Publications Verification

    Velcalcetide hydrochloride; AMG 416 hydrochloride; KAI-4169 hydrochloride

    		 CaSR Endocrinology
    Etelcalcetide hydrochloride (AMG 416 hydrochloride; KAI-4169 hydrochloride) is a synthetic calcimimetic as an activator of the calcium sensing receptor (CaSR). Etelcalcetide hydrochloride is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis, which is promising for research in the field of secondary hyperparathyroidism and chronic kidney disease .
    Etelcalcetide hydrochloride
  • HY-109106
    Upacicalcet

    		CaSR Endocrinology
    Upacicalcet is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels, by acting directly on parathyroid cell membrane calcium-sensing receptors. Upacicalcet can be used for researching the disease of secondary hyperparathyroidism (SHPT) .
    Upacicalcet
  • HY-P1955
    Etelcalcetide

    Velcalcetide; AMG 416; KAI-4169

    		 CaSR Metabolic Disease
    Etelcalcetide (AMG 416; KAI-4169) is a synthetic calcimimetic as an activator of the calcium sensing receptor (CaSR). Etelcalcetide is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis, which is promising for research in the field of secondary hyperparathyroidism and chronic kidney disease .
    Etelcalcetide
  • HY-50919
    Paricalcitol
    Maximum Cited Publications
    12 Publications Verification

    		 VD/VDR Metabolic Disease Cancer
    Paricalcitol, a vitamin D analogue, is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
    Paricalcitol
  • HY-76937
    Impurity of Doxercalciferol

    		VD/VDR Endocrinology
    Impurity of Doxercalciferol is an impurity of doxercalciferol, which is a synthetic analog of ergocalciferol (vitamin D2), used as a agent for secondary hyperparathyroidism and metabolic bone disease, and it suppresses parathyroid synthesis and secretion.
    Impurity of Doxercalciferol
  • HY-76585
    Paricalcitol-d6

    		VD/VDR Metabolic Disease
    Paricalcitol-d6 is the deuterium labeled Paricalcitol. Paricalcitol is a agent used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure[1].
    Paricalcitol-d6
  • HY-50919R
    Paricalcitol (Standard)

    		VD/VDR Metabolic Disease Cancer
    Paricalcitol (Standard) is the analytical standard of Paricalcitol. This product is intended for research and analytical applications. Paricalcitol, a vitamin D analogue, is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
    Paricalcitol (Standard)
  • HY-14863
    Lunacalcipol

    CTA-018

    		 VD/VDR Cytochrome P450 Others Endocrinology
    Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase. Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT) .
    Lunacalcipol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: